共 50 条
- [6] cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines EJC SUPPLEMENTS, 2010, 8 (07): : 83 - 84
- [10] Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma Current Oncology Reports, 2016, 18